The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
PI3K signaling in cancer: beyond AKT
Open accessAbstract
The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently altered pathways in human cancer and has a critical role in driving tumor initiation and progression. Although PI3K and its lipid product phosphatidylinositol-3,4,5-trisphosphate (PIP3) have been shown to activate multiple downstream signaling proteins, the vast majority of studies have focused on the protein kinase AKT as the dominant effector of PI3K signaling. However, recent studies have demonstrated many contexts under which other PIP3-dependent signaling proteins critically contribute to cancer progression, illustrating the importance of understanding AKT-independent signaling downstream of PI3K. Here, we highlight three PI3K-dependent, but AKT-independent, signaling branches that have recently been shown to have important roles in promoting phenotypes associated with malignancy. First, the PDK1 -mTORC2-SGK axis can substitute for AKT in survival, migration, and growth signaling and has emerged as a major mechanism of resistance to PI3K and AKT inhibitors. Second, Rac signaling mediates the reorganization of the actin cytoskeleton to regulate cancer cell migration, invasion, and metabolism. Finally, the TEC family kinase BTK has a critical role in B cell function and malignancy and represents a recent example of an effective therapeutic target in cancer. These mechanisms highlight how understanding PI3K-dependent, but AKT-independent, signaling mechanisms that drive cancer progression will be crucial for the development of novel and more effective approaches for targeting the PI3K pathway for therapeutic benefit in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Vetrie, D., Vořechovský, I., Sideras, P., Holland, J., Davies, A., Flinter, F., Hammarström, L., Kinnon, C., Levinsky, R., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,461
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I., Sparkes, R. S., Kubagawa, H., Mohandas, T., Quan, S., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,327
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Signalling through the lipid products of phosphoinositide-3-OH kinase
Toker, A., & Cantley, L. C. (1997) · Nature · doi:10.1038/42648 · Cited by 1,304
Self-citationThe nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Whitman, M., Downes, C. P., Keeler, M., Keller, T., & Cantley, L. (1988) · Nature · doi:10.1038/332644a0 · Cited by 1,016
Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement
Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., Sahai, E., & Marshall, C. J. (2008) · Cell · doi:10.1016/j.cell.2008.09.043 · Cited by 959
The WASP-WAVE protein network: Connecting the membrane to the cytoskeleton.
Takenawa, T., & Suetsugu, S. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2069 · Cited by 947
Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., & Cantley, L. C. (1989) · Cell · doi:10.1016/0092-8674(89)90182-7 · Cited by 908
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Sgk1-Dependent Stimulation of Cardiac Na+/H+Exchanger Nhe1 by Dexamethasone
Voelkl, J., Pasham, V., Ahmed, M. S. E., Walker, B., Szteyn, K., Kuhl, D., Metzler, B., Alesutan, I., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350120 · Cited by 857
Signaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
Regulation of mTORC1 by PI3K signaling
Dibble, C. C., & Cantley, L. C. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.06.002 · Cited by 836
Self-citationActivation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
PDK1, the master regulator of AGC kinase signal transduction
Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.022 · Cited by 810
Rho GTPase signalling in cell migration
Ridley, A. J. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.08.005 · Cited by 778
Melanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756
Alessi, D. R., Deak, M., Casamayor, A., Barry Caudwell, F., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00336-8 · Cited by 737
Defective B cell development and function in Btk-deficient mice
Khan, W. N., Alt, F. W., Gerstein, R. M., Malynn, B. A., Larsson, I., Rathbun, G., Davidson, L., Müller, S., Kantor, A. B., Herzenberg, L. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90114-0 · Cited by 726
(Patho)physiological Significance of the Serum- and Glucocorticoid-Inducible Kinase Isoforms
Lang, F., Böhmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., & Vallon, V. (2006) · Physiological Reviews · doi:10.1152/physrev.00050.2005 · Cited by 689
The regulation and function of Class III PI3Ks: novel roles for Vps34
Backer, J. M. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659
Damen, J. E., Liu, L., Rosten, P., Humphries, R. K., Jefferson, A. B., Majerus, P. W., & Krystal, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1689 · Cited by 633
Kobayashi, T., & Cohen, P. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390319 · Cited by 601
Park, J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3024 · Cited by 553
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J., Andritsos, L., Puri, K. D., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271171 · Cited by 543
Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis
Robey, R. B., & Hay, N. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.010 · Cited by 540
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M.-F., Lamberton, A., Mathieu, M., Bertrand, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1681 · Cited by 500
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB
Obata, T., Yaffe, M. B., Leparc, G. G., Piro, E. T., Maegawa, H., Kashiwagi, A., Kikkawa, R., & Cantley, L. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005497200 · Cited by 388
PtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase Complex
Liu, P., Gan, W., Chin, Y. R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L. C., Toker, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0460 · Cited by 382
Self-citationHu, H., Juvekar, A., Lyssiotis, C. A., Lien, E. C., Albeck, J. G., Oh, D., Varma, G., Hung, Y. P., Ullas, S., Lauring, J., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.042 · Cited by 380
Self-citationCurrie, R. A., Walker, K. S., Alex, G. R. A. Y., Deák, M., Casamayor, A., Downes, C. P., Cohen, P., Alessi, D. R., & Lucocq, J. M. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3370575 · Cited by 379
Shutes, A., Onesto, C., Picard, V., Leblond, B., Schweighoffer, F., & Der, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703571200 · Cited by 336
Phosphoinositide 3‐kinase‐dependent activation of Rac
Welch, H. C. E., Coadwell, W. J., Stephens, L. R., & Hawkins, P. T. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00454-x · Cited by 321
Bago, R., Malik, N., Munson, M. J., Prescott, A. R., Davies, P., Sommer, E., Shpiro, N., Ward, R., Cross, D., Ganley, I. G., et al. (2014) · Biochemical Journal · doi:10.1042/bj20140889 · Cited by 308
Impaired expansion of mouse B cell progenitors lacking Btk
Kerner, J. D., Appleby, M. W., Mohr, R. N., Chien, S., Rawlings, D. J., Maliszewski, C. R., Witte, O. N., & Perlmutte, R. M. (1995) · Immunity · doi:10.1016/1074-7613(95)90115-9 · Cited by 305
Biondi, R. M., Cheung, P. C. F., Casamayor, A., Deak, M., Currie, R. A., & Alessi, D. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.979 · Cited by 304
Pleckstrin homology (PH) domains and phosphoinositides
Lemmon, M. A. (2007) · Biochemical Society Symposium · doi:10.1042/bss0740081 · Cited by 298
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis
Bid, H. K., Roberts, R. D., Manchanda, P. K., & Houghton, P. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0164 · Cited by 265
Okkenhaug, K., Graupera, M., & Vanhaesebroeck, B. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0716 · Cited by 264
Pak protein kinases and their role in cancer
Dummler, B., Ohshiro, K., Kumar, R., & Field, J. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9168-1 · Cited by 259
The Src, Syk, and Tec family kinases: Distinct types of molecular switches
Bradshaw, J. M. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.03.001 · Cited by 256
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer
Chin, Y. R., & Toker, A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.015 · Cited by 255
Self-citationGlutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249
Self-citationActivation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a
Fine, B., Hodakoski, C., Koujak, S., Su, T., Saal, L. H., Maurer, M., Hopkins, B., Keniry, M., Sulis, M. L., Mense, S., et al. (2009) · Science · doi:10.1126/science.1173569 · Cited by 241
Pleckstrin homology (PH) domains and phosphoinositides
Lemmon, M. A. (2007) · Biochemical Society Symposia · doi:10.1042/bss2007c08 · Cited by 224
Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F. J., Kannan, S., Verma, C. S., Dickler, M., Chandarlapaty, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.004 · Cited by 222
Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase
Montalvo-Ortiz, B. L., Castillo-Pichardo, L., Hernández, E., Humphries-Bickley, T., De La Mota-Peynado, A., Cubano, L. A., Vlaar, C. P., & Dharmawardhane, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334524 · Cited by 213
Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer
Lien, E. C., Lyssiotis, C. A., & Cantley, L. C. (2016) · Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_3 · Cited by 212
Self-citationSherk, A. B., Frigo, D. E., Schnackenberg, C. G., Bray, J. D., Laping, N. J., Trizna, W., Hammond, M., Patterson, J. R., Thompson, S. K., Kazmin, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1047 · Cited by 211
Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer
Sosa, M. S., Lopez-Haber, C., Yang, C., Wang, H., Lemmon, M. A., Busillo, J. M., Luo, J., Benovic, J. L., Klein-Szanto, A., Yagi, H., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.11.029 · Cited by 210
Second-generation inhibitors of Bruton tyrosine kinase
Wu, J., Liu, C., Tsui, S. T., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0313-y · Cited by 210
Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate
Gan, X., Wang, J., Su, B., & Wu, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.195016 · Cited by 209
Pike, K. G., Malagu, K., Hummersone, M. G., Menear, K. A., Duggan, H. M. E., Gomez, S., Martin, N. M. B., Ruston, L., Pass, S. L., & Pass, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.019 · Cited by 207
Rac signaling in breast cancer: A tale of GEFs and GAPs
Wertheimer, E., Gutierrez-Uzquiza, A., Rosemblit, C., Lopez-Haber, C., Sosa, M. S., & Kazanietz, M. G. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.011 · Cited by 203
Optimization of WAVE2 complex–induced actin polymerization by membrane-bound IRSp53, PIP3, and Rac
Suetsugu, S., Kurisu, S., Oikawa, T., Yamazaki, D., Oda, A., & Takenawa, T. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200509067 · Cited by 185
Chin, Y. R., & Toker, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.031 · Cited by 184
Self-citationBalendran, A., Biondi, R. M., Cheung, P. C. F., Casamayor, A., Deak, M., & Alessi, D. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000421200 · Cited by 183
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis
Lindsay, C. R., Lawn, S., Campbell, A. D., Faller, W. J., Rambow, F., Mort, R. L., Timpson, P., Li, A., Cammareri, P., Ridgway, R. A., et al. (2011) · Nature Communications · doi:10.1038/ncomms1560 · Cited by 179
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
Sommer, E. M., Dry, H., Cross, D. A. E., Guichard, S. M., Davies, B. R., & Alessi, D. R. (2013) · Biochemical Journal · doi:10.1042/bj20130342 · Cited by 168
Park, W. S., Do Heo, W., Whalen, J. H., O'Rourke, N. A., Bryan, H. M., Meyer, T., & Teruel, M. N. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.008 · Cited by 167
Wisniewski, D., Strife, A., Swendeman, S., Erdjument-Bromage, H., Geromanos, S., Kavanaugh, W. M., Tempst, P., & Clarkson, B. (1999) · Blood · doi:10.1182/blood.v93.8.2707 · Cited by 162
SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
Gasser, J. A., Inuzuka, H., Lau, A. W., Wei, W., Beroukhim, R., & Toker, A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.023 · Cited by 149
Self-citationUpregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis
Qin, J., Xie, Y., Wang, B., Hoshino, M., Wolff, D. W., Zhao, J., Scofield, M. A., Dowd, F. J., Lin, M.-F., & Tu, Y. (2009) · Oncogene · doi:10.1038/onc.2009.30 · Cited by 142
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1
Najafov, A., Sommer, E. M., Axten, J. M., DeYoung, M. P., & Alessi, D. R. (2010) · Biochemical Journal · doi:10.1042/bj20101732 · Cited by 141
Désiré, L., Bourdin, J., Loiseau, N., Peillon, H., Picard, V., Oliveira, C. D., Bachelot, F., Leblond, B., Taverne, T., Beausoleil, E., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507913200 · Cited by 138
Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases
(2008) · Methods in Enzymology · doi:10.1016/s0076-6879(07)00409-0 · Cited by 126
EMD638683, a Novel SGK Inhibitor with Antihypertensive Potency
Ackermann, T. F., Boini, K. M., Beier, N., Scholz, W., Fuchß, T., & Lang, F. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000331722 · Cited by 121
Emerging Role of mTOR in the Response to Cancer Therapeutics
Ilagan, E., & Manning, B. D. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.03.008 · Cited by 119
Tam, C. S. L., Grigg, A., Opat, S., Ku, M., Gilbertson, M., Anderson, M. A., Seymour, J. F., Ritchie, D. S., DiCorleto, C., Dimovski, B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.832.832 · Cited by 111
Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
Gocek, E., Moulas, A. N., & Studzinski, G. P. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.874403 · Cited by 105
Signalling to cancer cell invasion through PAK family kinases
Whale, A. D. (2010) · Frontiers in bioscience · doi:10.2741/3724 · Cited by 101
The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model
Castillo‐Pichardo, L., Humphries‐Bickley, T., de la Parra, C., Forestier-Román, I., Martínez‐Ferrer, M., O'Farril, E. H., Vlaar, C. P., Ferrer‐Acosta, Y., Washington, A. V., Cubano, L. A., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.07.004 · Cited by 96
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Juvekar, A., Hu, H., Yadegarynia, S., Lyssiotis, C. A., Ullas, S., Lien, E. C., Bellinger, G., Son, J., Hok, R. C., Seth, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522223113 · Cited by 93
Self-citationCushing, T. D., Hao, X., Shin, Y., Andrews, K. L., Brown, M., Cardozo, M. G., Chen, Y., Duquette, J., Fisher, B., de Turiso, F. G.-L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501624r · Cited by 91
Bago, R., Sommer, E. M., Castel, P., Crafter, C., Bailey, F. P., Shpiro, N., Baselga, J. M., Cross, D. A. E., Eyers, P. A., & Alessi, D. R. (2016) · The EMBO Journal · doi:10.15252/embj.201693929 · Cited by 91
FOXO1 Transcription Factor: A Critical Effector of the PI3K-AKT Axis in B-Cell Development
Szydłowski, M., Jabłońska, E., & Juszczyński, P. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.885022 · Cited by 87
Rational Design and Applications of a Rac GTPase–Specific Small Molecule Inhibitor
Akbar, H., Cancelas, J. A., Williams, D. A., Zheng, J., & Zheng, Y. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)06043-5 · Cited by 85
PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion
Mense, S. M., Barrows, D., Hodakoski, C., Steinbach, N., Schoenfeld, D. A., Su, W., Hopkins, B. D., Su, T., Fine, B. M., Hibshoosh, H. H., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005840 · Cited by 81
Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J. L., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T., Burger, J. A., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140806 · Cited by 81
Tec Family Kinases in Inflammation and Disease
Horwood, N. J., Urbaniak, A. M., & Danks, L. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.670334 · Cited by 75
Targeted Disruption of the Protein Kinase SGK3/CISK Impairs Postnatal Hair Follicle Development
McCormick, J. A., Feng, Y., Dawson, K., Behne, M. J., Yu, B., Wang, J., Wyatt, A. W., Henke, G., Grahammer, F., Mauro, T. M., et al. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-01-0027 · Cited by 73
Talarico, C., Dattilo, V., D’Antona, L., Barone, A., Amodio, N., Belviso, S., Musumeci, F., Abbruzzese, C., Bianco, C., Trapasso, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7520 · Cited by 73
A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
Lee, C., Rattu, M. A., & Kim, S. S. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214561281 · Cited by 67
Gagliardi, P. A., di Blasio, L., Orso, F., Seano, G., Sessa, R., Taverna, D., Bussolino, F., & Primo, L. (2012) · Neoplasia · doi:10.1593/neo.12856 · Cited by 65
Talarico, C., D’Antona, L., Scumaci, D., Barone, A., Gigliotti, F., Fiumara, C. V., Dattilo, V., Gallo, E., Visca, P., Ortuso, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5527 · Cited by 62
Tessier, M., & Woodgett, J. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604333200 · Cited by 61
Lissanu, Y., Shi, Y., Rai, K., Nezi, L., Amin, S. B., Wu, C.-C., Akdemir, K. C., Mahdavi, M., Peng, Q., Chang, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513801113 · Cited by 60
Medina, J. R., Becker, C. J., Blackledge, C. W., Duquenne, C., Feng, Y., Grant, S. W., Heerding, D. A., Li, W. H. C., Miller, W. H., Romeril, S. P., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101527u · Cited by 56
SI113, a Specific Inhibitor of the Sgk1 Kinase Activity that Counteracts Cancer Cell Proliferation
D'Antona, L., Amato, R., Talarico, C., Ortuso, F., Menniti, M., Dattilo, V., Iuliano, R., Gigliotti, F., Artese, A., Costa, G., et al. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374008 · Cited by 55
Halland, N., Schmidt, F., Weiß, T., Saas, J., Li, Z., Czech, J., Dreyer, M., Hofmeister, A., Mertsch, K., Dietz, U., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5003376 · Cited by 46
Ortuso, F., Amato, R., Artese, A., D’Antona, L., Costa, G., Talarico, C., Gigliotti, F., Bianco, C., Trapasso, F., Schenone, S., et al. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500235f · Cited by 38
Pan, D., & Matsuura, Y. (2012) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309112007178 · Cited by 27
Phosphoinositide 3-Kinases—A Historical Perspective
Toker, A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-3012-0_4 · Cited by 23
Self-citationLocatelli, S. L., Careddu, G., Inghirami, G., Castagna, L., Sportelli, P., Santoro, A., & Carlo‐Stella, C. (2016) · Leukemia · doi:10.1038/leu.2016.224 · Cited by 13
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292
Brown, J. R., & Arnason, J. E. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s37419 · Cited by 6
Castillo‐Pichardo, L., Humphries‐Bickley, T., O'Farril, E. H., de la Parra, C., Cubano, L. A., Vlaar, C. P., & Flanagan, S. D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-a155 · Cited by 1
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Self-citationPI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
The anti-cancer effect of quercetin: molecular implications in cancer metabolism
Reyes-Farias, M., & Carrasco-Pozo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133177 · Cited by 689
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Metadata
- Authors
- Lien, E. C., Dibble, C. C., & Toker, A.
- Venue
- Current Opinion in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 45
- Pages
- 62-71
- ISSN
- 0955-0674 (ISSN-L)
- OpenAlex
- W2598705813
- Cited by
- 451
- References
- 114
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.